Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods

Drug Metabolism and Disposition

Volumn 41, Issue 1, 2013, Pages 149-158

  Ishiguro, Naoki ^a   Shimizu, Hidetada ^a   Kishimoto, Wataru ^a   Ebner, Thomas ^b   Schaefer, Olaf ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARNITINE TRANSPORTER 1; CARNITINE TRANSPORTER 2; CARRIER PROTEIN; LINAGLIPTIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN HEK293; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; LLC-PK1 CELLS; P-GLYCOPROTEIN; PURINES; QUINAZOLINES; SWINE;

EID: 84871551884     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.048470     Document Type: Article

References (45)

1. Ayrton A and Morgan P (2001) Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497. (Pubitemid 32826389)
2. Bergman A, Ebel D, Liu F, Stone J, Wang A, Zeng W, Chen L, Dilzer S, Lasseter K, and Herman G, et al. (2007) Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers. Biopharm Drug Dispos 28:315-322. (Pubitemid 47439637)
3. Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, and Wagner K (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38:667-678.
4. Boehringer Ingelheim Pharmaceuticals (2011) Tradjenta™ (linagliptin) tablets. Food and Drug Administration; available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201280lbl.pdf; accessed on 2012 July 10.
5. Center for Drug Evaluation and Research (2003) Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Food and Drug Administration; available at: http://www.fda.gov/downloads/Drugs/Guidance-ComplianceRegulatoryInformation/ Guidances/ucm070124.pdf; accessed on 2012 July 10.
6. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660. (Pubitemid 30390404)
7. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, Xu S, Bergman AJ, Braun MP, and Dean DC, et al. (2007) Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 321:673-683. (Pubitemid 46624514)
8. Deacon CF and Holst JJ (2010) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs 19:133-140.
9. Dresser MJ, Leabman MK, and Giacomini KM (2001) Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J Pharm Sci 90:397-421. (Pubitemid 32298045)
10. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705. (Pubitemid 46048557)
11. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LC, Paulusma CC, Oude, Elferink RP, Baas F, and Schinkel AH, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 101:1310-1319. (Pubitemid 28166828)
12. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, and Dugi KA (2011) The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes Obes Metab 13:542-550.
13. Fricker G and Miller DS (2002) Relevance of multidrug resistance proteins for intestinal drug absorption in vitro and in vivo. Pharmacol Toxicol 90:5-13. (Pubitemid 34165254)
14. Friedrich C, Ring A, Brand T, Sennewald R, Graefe-Mody EU, and Woerle HJ (2011) Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. Eur J Drug Metab Pharmacokinet 36:17-24.
15. Fuchs H, Binder R, and Greischel A (2009a) Tissue distribution of the novel DPP-4 inhibitor BI 1356 is dominated by saturable binding to its target in rats. Biopharm Drug Dispos 30:229-240.
16. Fuchs H, Runge F, and Held H-D (2012) Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci 45:533-538.
17. Fuchs H, Tillement JP, Urien S, Greischel A, and Roth W (2009b) Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 61:55-62.
18. Giacomini KM, Huang SM, and Tweedie DJ, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
19. Goh LB, Spears KJ, Yao D, Ayrton A, Morgan P, Roland Wolf C, and Friedberg T (2002) Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man. Biochem Pharmacol 64:1569-1578. (Pubitemid 35333418)
20. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, Halabi A, and Woerle HJ (2011) Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin(*). Diabetes Obes Metab 13:939-946.
21. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, and Dugi KA (2009) Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 11:786-794.
22. Herman GA, Stevens C, Van Dyck K, and Bergman AYi BDe Smet MSnyder KHilliard DTanen MTanaka W, et al. (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78:675-688. (Pubitemid 41773643)
23. Hirano M, Maeda K, Shitara Y, and Sugiyama Y (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146. (Pubitemid 39287793)
24. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, and Dugi KA (2008) Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 48:1171-1178.
25. Ishiguro N, Maeda K, Saito A, Kishimoto W, Matsushima S, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2008) Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide. Drug Metab Dispos 36:796-805. (Pubitemid 351468387)
26. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, and Tamai I (2005) Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 33: 1791-1795. (Pubitemid 41697263)
27. Kusuhara H and Sugiyama Y (2002) Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J Control Release 78:43-54. (Pubitemid 34081852)
28. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959. (Pubitemid 32652819)
29. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
30. Minuesa G, Volk C, Molina-Arcas M, Gorboulev V, Erkizia I, Arndt P, Clotet B, Pastor-Anglada M, Koepsell H, and Martinez-Picado J (2009) Transport of lamivudine [(-)-beta-L-2′,3′-dideoxy-3′-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther 329:252-261.
31. Mizuno N, Niwa T, Yotsumoto Y, and Sugiyama Y (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol Rev 55:425-461. (Pubitemid 37013212)
32. Müller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, de Vries EG, and Jansen PL (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037.
33. Nauck MA (2011) Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 124 (1 Suppl):S3-S18.
34. Neumiller JJ and Setter SM (2012) Review of linagliptin for the treatment of type 2 diabetes mellitus. Clin Ther 34:993-1005.
35. Retlich S, Duval V, Ring A, Staab A, Hüttner S, Jungnik A, Jaehde U, Dugi KA, and Graefe-Mody U (2010) Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects. Clin Pharmacokinet 49:829-840.
36. Retlich S, Withopf B, Greischel A, Staab A, Jaehde U, and Fuchs H (2009) Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats. Biopharm Drug Dispos 30:422-436.
37. Scheen AJ (2010) Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12:648-658.
38. Shimizu M, Fuse K, Okudaira K, Nishigaki R, Maeda K, Kusuhara H, and Sugiyama Y (2005) Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans. Drug Metab Dispos 33:1477-1481. (Pubitemid 41323995)
39. Tamai I, Ohashi R, Nezu J, Yabuuchi H, Oku A, Shimane M, Sai Y, and Tsuji A (1998) Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273:20378-20382. (Pubitemid 28377603)
40. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, and Tsuji A (1997) Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419:107-111. (Pubitemid 28011227)
41. Tang F, Horie K, and Borchardt RT (2002) Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res 19:773-779. (Pubitemid 34686735)
42. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, and Hori R (1992) Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
43. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, and Mark M (2008) (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182. (Pubitemid 351439162)
44. Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, and Hori R (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252.
45. Zhang L, Zhang YD, Strong JM, Reynolds KS, and Huang SM (2008) A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38:709-724.